The Mayo Clinic has already been an important investor and development partner for the Westport, Conn.–based company. BioSig signed a 10-year collaboration agreement with Mayo Clinic in March 2017, signing three new patent and know-how license agreements with the Mayo foundation in November 2019.
The new R&D collaboration, announced yesterday, will find ways to use artificial intelligence and machine learning to boost the clinical value of Pure EP and its proprietary hardware and software with advanced signal processing capabilities. Dr. Samuel J. Asirvatham, Mayo Clinic’s vice chair of innovation and Electrophysiology Laboratory medical director, and Alexander D. Wissner-Gross, managing director of Reified, will lead the research effort.
“Artificial intelligence presents a variety of novel opportunities for extracting clinically actionable information from existing electrophysiological signals that might otherwise be inaccessible. We are excited to contribute to the advancement of this field,” Wissner-Gross said in a news release.
BioSig CEO Kenneth L Londoner said he thinks the collaboration will enable the company and its partners to “develop powerful applications and help pave the way toward improved patient outcomes in cardiology and beyond.”